Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Thyroid Neoplasms 1Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Peritoneal Neoplasms 1Pain 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Follicular 1Lung Neoplasms 1Kidney Neoplasms 1Hypothyroidism 1Hepatic Encephalopathy 1Goiter 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Cancer Pain 1Breast Neoplasms 1

Interventions

Oxycodone 5Morphine 5nabiximols 4Naloxone 2Fentanyl 26'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2tanezumab 1naloxegol 1incobotulinumtoxinA 1Water 1Transcranial Direct Current Stimulation 1Tapentadol 1Sodium Bicarbonate 1Methadone 1Lidocaine 1Lenalidomide 1Ketamine 1Inosine Monophosphate 1Hydromorphone 1Glucose 1Donepezil 1Cognitive Behavioral Therapy 1Buprenorphine 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cancer Pain × Glucose × Clear all
NCT01384877 2019-07-12

Subcutaneous Lidocaine For Cancer-Related Pain

British Columbia Cancer Agency

Phase 2/3 Completed
33 enrolled 16 charts

Cancer Pain, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡